EyePoint Pharmaceuticals Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of EyePoint Pharmaceuticals Inc Company

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.

EyePoint Pharmaceuticals Inc Info



Ticker SymbolEYPT

Company nameEyePoint Pharmaceuticals Inc

IPO dateJan 27, 2005

CEODr. Jay S. Duker, M.D.

Number of employees165

Security typeOrdinary Share

Fiscal year-endJan 27

Address480 Pleasant Street, Suite C400

CityWATERTOWN

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited States of America

Postal code02472

Phone16179265000

Websitehttps://eyepointpharma.com/

Ticker SymbolEYPT

IPO dateJan 27, 2005

CEODr. Jay S. Duker, M.D.

Company Executives of EyePoint Pharmaceuticals Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

685.61K

+1.33%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

575.46K

+1.97%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+567.59%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+1.73%

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

107.43K

+977.87%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

--

Mr. Ramiro Ribeiro, M.D., Ph.D.

Chief Medical Officer

41.78K

--

Dr. Reginald J Sanders, M.D.

Non-Executive Independent Director

--

Mr. Fred Hassan

Non-Executive Independent Director

--

Mr. Stern

Investor Relations

--

Name

Name/Position

Position

Shareholding

Change

Dr. Jay S. Duker, M.D.

President, Chief Executive Officer, Director

685.61K

+1.33%

Ms. Nancy S. Lurker

Executive Vice Chairman of the Board

575.46K

+1.97%

Dr. John B. Landis, Ph.D.

Non-Executive Independent Director

142.86K

+567.59%

Ms. Karen L. Zaderej

Non-Executive Independent Director

117.28K

+1.73%

Ms. Wendy F. Dicicco, CPA

Non-Executive Independent Director

107.43K

+977.87%

Mr. Stuart Duty

Non-Executive Independent Director

45.01K

--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2024

FY2023

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

YUTIQ

3.10M

7.16%

By RegionUSD

Name

Revenue

Proportion

United States

42.05M

97.17%

China

1.12M

2.60%

United Kingdom

100.00K

0.23%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

YUTIQ

3.10M

7.16%

Shareholding Stats

Updated: Sat, Aug 16

Shareholders

Shareholder Types

Shareholders

Proportion

Cormorant Asset Management, LP

10.06%

Suvretta Capital Management, LLC

8.22%

Adage Capital Management, L.P.

8.21%

BlackRock Institutional Trust Company, N.A.

5.56%

Franklin Advisers, Inc.

5.15%

Other

62.80%

Shareholders

Proportion

Cormorant Asset Management, LP

10.06%

Suvretta Capital Management, LLC

8.22%

Adage Capital Management, L.P.

8.21%

BlackRock Institutional Trust Company, N.A.

5.56%

Franklin Advisers, Inc.

5.15%

Other

62.80%

Shareholder Types

Shareholders

Proportion

Hedge Fund

33.33%

Investment Advisor

23.07%

Investment Advisor/Hedge Fund

20.71%

Research Firm

3.68%

Individual Investor

2.96%

Venture Capital

2.92%

Private Equity

1.68%

Bank and Trust

0.95%

Pension Fund

0.14%

Other

10.56%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

378

69.28M

83.75%

-19.64M

2025Q2

385

78.45M

113.85%

-10.49M

2025Q1

386

76.27M

110.90%

-11.90M

2024Q4

373

75.75M

111.39%

+202.32K

2024Q3

358

60.55M

112.89%

-8.01M

2024Q2

345

60.80M

116.35%

-2.75M

2024Q1

328

57.32M

114.97%

+528.95K

2023Q4

282

52.72M

108.16%

+11.49M

2023Q3

239

37.39M

106.16%

-1.26M

2023Q2

224

35.30M

102.90%

-4.83M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Cormorant Asset Management, LP

8.32M

12.08%

--

Jun 30, 2025

Suvretta Capital Management, LLC

6.80M

9.87%

--

Jun 30, 2025

Adage Capital Management, L.P.

6.80M

9.87%

+600.00K

+9.68%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.60M

6.67%

-346.31K

-7.00%

Jun 30, 2025

Franklin Advisers, Inc.

4.27M

6.19%

+148.48K

+3.60%

Jun 30, 2025

The Vanguard Group, Inc.

3.80M

5.52%

-15.98K

-0.42%

Jun 30, 2025

Federated Hermes Global Investment Management Corp.

3.58M

5.2%

-128.17K

-3.45%

Jun 30, 2025

TCG Crossover Management, LLC

3.57M

5.18%

--

Jun 30, 2025

Citadel Advisors LLC

2.34M

3.4%

+58.12K

+2.54%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.59M

2.31%

-982.00

-0.06%

Jun 30, 2025

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

Virtus LifeSci Biotech Clinical Trials ETF

1.16%

Simplify Health Care ETF

1.02%

SPDR S&P Pharmaceuticals ETF

0.98%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0.73%

Invesco Dorsey Wright SmallCap Momentum ETF

0.39%

Federated Hermes MDT Small Cap Core ETF

0.3%

iShares Micro-Cap ETF

0.16%

Invesco Nasdaq Biotechnology ETF

0.1%

Vanguard US Momentum Factor ETF

0.1%

ProShares Ultra Nasdaq Biotechnology

0.1%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion1.16%

Simplify Health Care ETF

Proportion1.02%

SPDR S&P Pharmaceuticals ETF

Proportion0.98%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proportion0.73%

Invesco Dorsey Wright SmallCap Momentum ETF

Proportion0.39%

Federated Hermes MDT Small Cap Core ETF

Proportion0.3%

iShares Micro-Cap ETF

Proportion0.16%

Invesco Nasdaq Biotechnology ETF

Proportion0.1%

Vanguard US Momentum Factor ETF

Proportion0.1%

ProShares Ultra Nasdaq Biotechnology

Proportion0.1%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Date

Type

Ratio

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1

Dec 08, 2020

Merger

10→1